Survival and prognostic factors in patients with gastrointestinal cancers and brain metastases: have we made progress?

[1]  P. Brown,et al.  Estimating survival for renal cell carcinoma patients with brain metastases: an update of the Renal Graded Prognostic Assessment tool , 2018, Neuro-oncology.

[2]  P. Brown,et al.  Effect of Targeted Therapies on Prognostic Factors, Patterns of Care, and Survival in Patients With Renal Cell Carcinoma and Brain Metastases. , 2018, International journal of radiation oncology, biology, physics.

[3]  James X. Sun,et al.  Targeting HER2 in colorectal cancer: The landscape of amplification and short variant mutations in ERBB2 and ERBB3 , 2018, Cancer.

[4]  Wen Jiang,et al.  Estimating Survival in Melanoma Patients With Brain Metastases: An Update of the Graded Prognostic Assessment for Melanoma Using Molecular Markers (Melanoma-molGPA). , 2017, International journal of radiation oncology, biology, physics.

[5]  J. Pignon,et al.  Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials † , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  P. Brown,et al.  The Prognostic Value of BRAF, C-KIT, and NRAS Mutations in Melanoma Patients With Brain Metastases. , 2017, International journal of radiation oncology, biology, physics.

[7]  P. Brown,et al.  Estimating Survival in Patients With Lung Cancer and Brain Metastases: An Update of the Graded Prognostic Assessment for Lung Cancer Using Molecular Markers (Lung-molGPA) , 2017, JAMA oncology.

[8]  D. Sargent,et al.  Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer , 2017, Journal of the National Cancer Institute.

[9]  D. Sargent,et al.  Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers: A Secondary Analysis of 2 Randomized Clinical Trials , 2017, JAMA oncology.

[10]  Ruth E Langley,et al.  Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial , 2016, The Lancet.

[11]  P. Brown,et al.  The Effect of Gene Alterations and Tyrosine Kinase Inhibition on Survival and Cause of Death in Patients With Adenocarcinoma of the Lung and Brain Metastases. , 2016, International journal of radiation oncology, biology, physics.

[12]  Volker W Stieber,et al.  Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases: A Randomized Clinical Trial. , 2016, JAMA.

[13]  Bert Vogelstein,et al.  PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. , 2015, The New England journal of medicine.

[14]  A. Mehrabi,et al.  Brain metastasis from gastrointestinal cancers: a systematic review , 2014, International journal of clinical practice.

[15]  P. Brown,et al.  Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. , 2012, International journal of radiation oncology, biology, physics.

[16]  Stef van Buuren,et al.  Flexible Imputation of Missing Data , 2012 .

[17]  Xianghua Luo,et al.  Summary report on the graded prognostic assessment: an accurate and facile diagnosis-specific tool to estimate survival for patients with brain metastases. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  R. Labianca,et al.  DNA mismatch repair status and colon cancer recurrence and survival in clinical trials of 5-fluorouracil-based adjuvant therapy. , 2011, Journal of the National Cancer Institute.

[19]  L. Collette,et al.  Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Yoon-Koo Kang,et al.  Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial , 2010, The Lancet.

[21]  P. Brown,et al.  Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4,259 patients. , 2009, International journal of radiation oncology, biology, physics.

[22]  K. Hess,et al.  Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. , 2009, The Lancet. Oncology.

[23]  A. Jimeno,et al.  HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  Hiroki Shirato,et al.  Stereotactic Radiosurgery Plus Whole-Brain Radiation Therapy vs Stereotactic Radiosurgery Alone for Treatment of Brain Metastases: A Randomized Controlled Trial , 2007 .

[25]  J. Posner,et al.  Brain metastases: epidemiology and pathophysiology , 2005, Journal of Neuro-Oncology.

[26]  S. Bartelt,et al.  Patients with brain metastases from gastrointestinal tract cancer treated with whole brain radiation therapy: prognostic factors and survival. , 2004, World journal of gastroenterology.

[27]  Frank E. Harrell,et al.  Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression, and Survival Analysis , 2001 .

[28]  P. Grambsch,et al.  Proportional hazards tests and diagnostics based on weighted residuals , 1994 .

[29]  C. Atreya,et al.  Prolonged Response to HER2-Directed Therapy in a Patient With HER2-Amplified, Rapidly Progressive Metastatic Colorectal Cancer. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[30]  R. Chamberlain,et al.  Gastrointestinal Cancer and Brain Metastasis Outcomes and Management , 2015 .

[31]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .